RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer

Overview of attention for article published in Future Oncology, August 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 3 news outlets

twitter: 7 X users

Readers on

mendeley: 27 Mendeley

So far, Altmetric has seen 11 X posts from 7 X users, with an upper bound of 23,960 followers.

RT @dsmgyo: Now open UT Southwestern Simmons Comprehensive Cancer Center (@utswcancer) & @parkland. @GOG 3028 #gyncsm . https://t.co…

Now open UT Southwestern Simmons Comprehensive Cancer Center (@utswcancer) & @parkland. @GOG 3028 #gyncsm . https://t.co/EH4HL0nOrM

$AGEN

RT @_B_I_O_T_E_C_H_: $AGEN Responses were durable, as evidenced by a median DOR of 15.4 months. In contrast to other PD-1 inhibitors evalua…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 7 additional X posts.